Literature DB >> 21212667

Abciximab does not prevent ischemic lesions related to cerebral angiography: a randomized placebo-controlled trial.

Carolin Brockmann1, Thomas Hoefer, Michael Diepers, Eva Neumaier-Probst, Ingo Noelte, Marc-Alexander Brockmann, Christel Weiss, Christoph Groden, Johann Scharf.   

Abstract

BACKGROUND: To assess the efficiency of IIb/IIIa platelet receptor inhibition by abciximab in the prevention of silent embolism during digital subtraction angiography.
METHODS: In this randomized, double-blind, prospective study, pre- and postangiographic diffusion-weighted magnetic resonance imaging (DWI) of 184 participants was evaluated for the occurrence of silent embolism.
RESULTS: No significant relationship was found between the patients receiving abciximab before digital subtraction angiography (15 of 90; 16.7%) and patients in the placebo group (16 of 94; 17.0%) regarding postangiographic appearance of silent emboli (p = 0.9).
CONCLUSIONS: IIb/IIIa receptor inhibition by abciximab does not diminish the occurrence of silent embolism during digital subtraction angiography. Our findings indicate that solid blood clots are not the origin of hyperintense lesions observed on DWI and enhance the role of alternative mechanisms.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212667     DOI: 10.1159/000323219

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  4 in total

Review 1.  Anticoagulation in neurointerventions: basic pharmacology and pathophysiology, current status, practical advice.

Authors:  J Scharf; C-E Dempfle
Journal:  Clin Neuroradiol       Date:  2012-02-07       Impact factor: 3.649

Review 2.  Intra-Arterial Delivery of Cell Therapies for Stroke.

Authors:  Raphael Guzman; Miroslaw Janowski; Piotr Walczak
Journal:  Stroke       Date:  2018-04-18       Impact factor: 7.914

3.  Thromboembolic complications in patients with clopidogrel resistance after coil embolization for unruptured intracranial aneurysms.

Authors:  B Kim; K Kim; P Jeon; S Kim; H Kim; H Byun; J Cha; S Hong; K Jo
Journal:  AJNR Am J Neuroradiol       Date:  2014-05-15       Impact factor: 3.825

4.  Safety of intra-arterial chemotherapy with or without osmotic blood-brain barrier disruption for the treatment of patients with brain tumors.

Authors:  Kutluay Uluc; Prakash Ambady; Matthew K McIntyre; John Philip Tabb; Cymon N Kersch; Caleb S Nerison; Amy Huddleston; Jesse J Liu; Aclan Dogan; Ryan A Priest; Rongwei Fu; Joao Prola Netto; Dominic A Siler; Leslie L Muldoon; Seymur Gahramanov; Edward A Neuwelt
Journal:  Neurooncol Adv       Date:  2022-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.